Abstract 5737: Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies

Background: Following MET inhibitor and checkpoint inhibitor approvals, it is essential to identify cancer indications that harbor molecular alterations of interest and a thorough real-world molecular genomics based characterization of those tumors would allow to expand cancer specific indications t...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2022-06, Vol.82 (12_Supplement), p.5737-5737
Main Authors: Feng, Zheng, Pignon, Jean-Christophe, Sharaf, Radwa, Romanov, Natalie, Doudement, Julien, Albacker, Lee A., Kurata, Noriaki, Smith, Neil R., Matsushita, Nobutoshi, Scheuenpflug, Juergen
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c987-1702dcc07cc441b655e53527c732c08fdb4c00f4e462b05e02251048fc6e81883
cites
container_end_page 5737
container_issue 12_Supplement
container_start_page 5737
container_title Cancer research (Chicago, Ill.)
container_volume 82
creator Feng, Zheng
Pignon, Jean-Christophe
Sharaf, Radwa
Romanov, Natalie
Doudement, Julien
Albacker, Lee A.
Kurata, Noriaki
Smith, Neil R.
Matsushita, Nobutoshi
Scheuenpflug, Juergen
description Background: Following MET inhibitor and checkpoint inhibitor approvals, it is essential to identify cancer indications that harbor molecular alterations of interest and a thorough real-world molecular genomics based characterization of those tumors would allow to expand cancer specific indications that might benefit from MET and checkpoint inhibitors and shed light on exploring clinically efficacious combo strategies. Importantly, such an approach provides the end-to-end solutions that shall significantly contribute to clinical translation and/or back translation strategies for innovative cancer therapies. Methods: We systemically interrogated FoundationInsights®, a dataset of real-world molecular genomic tumor profiling from North American patients, and investigated the prevalence of MET amplifications, METex14 skipping and MET fusions prevalence in 62110 unique patient samples across five indications (lung adenocarcinoma [LUAD], esophageal/gastroesophageal-junction/stomach adenocarcinoma [Eso/GEJ/Sto], papillary renal cell carcinoma, hepatocellular carcinoma [HCC] and glioblastoma). MET alteration prevalence was further categorized based on tumor cell PD-L1 IHC status (22C3 pharmDx) and TMB status. Additionally, comprehensive text mining from clinicaltrials.gov and landscape overview were conducted. Results: MET amplification was the most frequent MET alteration examined with a prevalence ranging from 1.4% in HCC to 4.8% in Eso/GEJ/Sto. In HCC and LUAD, MET amplification prevalence was higher in tumors with high TMB (≥10 mutations/megabase, P
doi_str_mv 10.1158/1538-7445.AM2022-5737
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1538_7445_AM2022_5737</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1158_1538_7445_AM2022_5737</sourcerecordid><originalsourceid>FETCH-LOGICAL-c987-1702dcc07cc441b655e53527c732c08fdb4c00f4e462b05e02251048fc6e81883</originalsourceid><addsrcrecordid>eNpNkd1OwzAMhSsEEmPwCEh-gBWStlkKd2OMH2kTu9h9lbpuFdQmUxIx7fF4MxoNIa5sH9lH1neS5JazO85Fec9FXqayKMTdYpOxLEuFzOVZMvnTz__1l8mV95-MMcGZmCTfi9oHpzBAPHqErSPUXlsD1qDtbXeExukvMuBI9XCwrm8Ae200jmNHxg4aPTQqKBhG1XRgW9isdqD6QE6F0crPYLd5moEyDWyf1ymHYIGGvT2QA22a0SqugeqM9UEj7MeZTAAyzvb9ENt4i3aotTntxqcDdZr8dXLRqt7TzW-dJruX1W75lq4_Xt-Xi3WKD6VMuWRZg8gkYlHwei4EiVxkEmWeISvbpi6QsbagYp7VTNCIcQRUlC3OqeRlmU8TcbJFZ7131FZ7pwfljhVnVYyhioiriLg6xVBFovkPtdV93w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract 5737: Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies</title><source>EZB Electronic Journals Library</source><creator>Feng, Zheng ; Pignon, Jean-Christophe ; Sharaf, Radwa ; Romanov, Natalie ; Doudement, Julien ; Albacker, Lee A. ; Kurata, Noriaki ; Smith, Neil R. ; Matsushita, Nobutoshi ; Scheuenpflug, Juergen</creator><creatorcontrib>Feng, Zheng ; Pignon, Jean-Christophe ; Sharaf, Radwa ; Romanov, Natalie ; Doudement, Julien ; Albacker, Lee A. ; Kurata, Noriaki ; Smith, Neil R. ; Matsushita, Nobutoshi ; Scheuenpflug, Juergen</creatorcontrib><description>Background: Following MET inhibitor and checkpoint inhibitor approvals, it is essential to identify cancer indications that harbor molecular alterations of interest and a thorough real-world molecular genomics based characterization of those tumors would allow to expand cancer specific indications that might benefit from MET and checkpoint inhibitors and shed light on exploring clinically efficacious combo strategies. Importantly, such an approach provides the end-to-end solutions that shall significantly contribute to clinical translation and/or back translation strategies for innovative cancer therapies. Methods: We systemically interrogated FoundationInsights®, a dataset of real-world molecular genomic tumor profiling from North American patients, and investigated the prevalence of MET amplifications, METex14 skipping and MET fusions prevalence in 62110 unique patient samples across five indications (lung adenocarcinoma [LUAD], esophageal/gastroesophageal-junction/stomach adenocarcinoma [Eso/GEJ/Sto], papillary renal cell carcinoma, hepatocellular carcinoma [HCC] and glioblastoma). MET alteration prevalence was further categorized based on tumor cell PD-L1 IHC status (22C3 pharmDx) and TMB status. Additionally, comprehensive text mining from clinicaltrials.gov and landscape overview were conducted. Results: MET amplification was the most frequent MET alteration examined with a prevalence ranging from 1.4% in HCC to 4.8% in Eso/GEJ/Sto. In HCC and LUAD, MET amplification prevalence was higher in tumors with high TMB (≥10 mutations/megabase, P&lt;0.05). In Eso/GEJ/Sto and LUAD, MET amplification occurrence was higher in PD-L1-high tumor vs. PD-L1-low or PD-L1-neg tumors (P&lt;0.05). METex14 skipping mutations were observed in LUAD (2.3%), rarely in the other five tumor types analyzed (≤0.1%). Lastly in LUAD, METex14 skipping mutations were more frequent in PD-L1 high tumors but not those with high TMB (P&lt;0.05). Text mining results indicate that- while most trials use MET amplification for patient stratification- there is a distinct tendency for MET inhibitor trials to increasingly include METex14 skipping as a major selection criterion as well. Conclusions: Real world genomics corroborated MET amplification as a predominant MET alteration across various indication. The potential clinical benefit to combine MET inhibitors with PD-1/PD-L1 blockades in specific indications and specific subsets of patients is further recognized. Collectively, the comprehensive molecular profiling &amp; text mining approaches will continue to guide application of precision medicine in clinical trial design based on appropriate biomarker selection. Citation Format: Zheng Feng, Jean-Christophe Pignon, Radwa Sharaf, Natalie Romanov, Julien Doudement, Lee A. Albacker, Noriaki Kurata, Neil R. Smith, Nobutoshi Matsushita, Juergen Scheuenpflug. Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5737.</description><identifier>ISSN: 1538-7445</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2022-5737</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5737-5737</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c987-1702dcc07cc441b655e53527c732c08fdb4c00f4e462b05e02251048fc6e81883</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Feng, Zheng</creatorcontrib><creatorcontrib>Pignon, Jean-Christophe</creatorcontrib><creatorcontrib>Sharaf, Radwa</creatorcontrib><creatorcontrib>Romanov, Natalie</creatorcontrib><creatorcontrib>Doudement, Julien</creatorcontrib><creatorcontrib>Albacker, Lee A.</creatorcontrib><creatorcontrib>Kurata, Noriaki</creatorcontrib><creatorcontrib>Smith, Neil R.</creatorcontrib><creatorcontrib>Matsushita, Nobutoshi</creatorcontrib><creatorcontrib>Scheuenpflug, Juergen</creatorcontrib><title>Abstract 5737: Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies</title><title>Cancer research (Chicago, Ill.)</title><description>Background: Following MET inhibitor and checkpoint inhibitor approvals, it is essential to identify cancer indications that harbor molecular alterations of interest and a thorough real-world molecular genomics based characterization of those tumors would allow to expand cancer specific indications that might benefit from MET and checkpoint inhibitors and shed light on exploring clinically efficacious combo strategies. Importantly, such an approach provides the end-to-end solutions that shall significantly contribute to clinical translation and/or back translation strategies for innovative cancer therapies. Methods: We systemically interrogated FoundationInsights®, a dataset of real-world molecular genomic tumor profiling from North American patients, and investigated the prevalence of MET amplifications, METex14 skipping and MET fusions prevalence in 62110 unique patient samples across five indications (lung adenocarcinoma [LUAD], esophageal/gastroesophageal-junction/stomach adenocarcinoma [Eso/GEJ/Sto], papillary renal cell carcinoma, hepatocellular carcinoma [HCC] and glioblastoma). MET alteration prevalence was further categorized based on tumor cell PD-L1 IHC status (22C3 pharmDx) and TMB status. Additionally, comprehensive text mining from clinicaltrials.gov and landscape overview were conducted. Results: MET amplification was the most frequent MET alteration examined with a prevalence ranging from 1.4% in HCC to 4.8% in Eso/GEJ/Sto. In HCC and LUAD, MET amplification prevalence was higher in tumors with high TMB (≥10 mutations/megabase, P&lt;0.05). In Eso/GEJ/Sto and LUAD, MET amplification occurrence was higher in PD-L1-high tumor vs. PD-L1-low or PD-L1-neg tumors (P&lt;0.05). METex14 skipping mutations were observed in LUAD (2.3%), rarely in the other five tumor types analyzed (≤0.1%). Lastly in LUAD, METex14 skipping mutations were more frequent in PD-L1 high tumors but not those with high TMB (P&lt;0.05). Text mining results indicate that- while most trials use MET amplification for patient stratification- there is a distinct tendency for MET inhibitor trials to increasingly include METex14 skipping as a major selection criterion as well. Conclusions: Real world genomics corroborated MET amplification as a predominant MET alteration across various indication. The potential clinical benefit to combine MET inhibitors with PD-1/PD-L1 blockades in specific indications and specific subsets of patients is further recognized. Collectively, the comprehensive molecular profiling &amp; text mining approaches will continue to guide application of precision medicine in clinical trial design based on appropriate biomarker selection. Citation Format: Zheng Feng, Jean-Christophe Pignon, Radwa Sharaf, Natalie Romanov, Julien Doudement, Lee A. Albacker, Noriaki Kurata, Neil R. Smith, Nobutoshi Matsushita, Juergen Scheuenpflug. Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5737.</description><issn>1538-7445</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpNkd1OwzAMhSsEEmPwCEh-gBWStlkKd2OMH2kTu9h9lbpuFdQmUxIx7fF4MxoNIa5sH9lH1neS5JazO85Fec9FXqayKMTdYpOxLEuFzOVZMvnTz__1l8mV95-MMcGZmCTfi9oHpzBAPHqErSPUXlsD1qDtbXeExukvMuBI9XCwrm8Ae200jmNHxg4aPTQqKBhG1XRgW9isdqD6QE6F0crPYLd5moEyDWyf1ymHYIGGvT2QA22a0SqugeqM9UEj7MeZTAAyzvb9ENt4i3aotTntxqcDdZr8dXLRqt7TzW-dJruX1W75lq4_Xt-Xi3WKD6VMuWRZg8gkYlHwei4EiVxkEmWeISvbpi6QsbagYp7VTNCIcQRUlC3OqeRlmU8TcbJFZ7131FZ7pwfljhVnVYyhioiriLg6xVBFovkPtdV93w</recordid><startdate>20220615</startdate><enddate>20220615</enddate><creator>Feng, Zheng</creator><creator>Pignon, Jean-Christophe</creator><creator>Sharaf, Radwa</creator><creator>Romanov, Natalie</creator><creator>Doudement, Julien</creator><creator>Albacker, Lee A.</creator><creator>Kurata, Noriaki</creator><creator>Smith, Neil R.</creator><creator>Matsushita, Nobutoshi</creator><creator>Scheuenpflug, Juergen</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20220615</creationdate><title>Abstract 5737: Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies</title><author>Feng, Zheng ; Pignon, Jean-Christophe ; Sharaf, Radwa ; Romanov, Natalie ; Doudement, Julien ; Albacker, Lee A. ; Kurata, Noriaki ; Smith, Neil R. ; Matsushita, Nobutoshi ; Scheuenpflug, Juergen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c987-1702dcc07cc441b655e53527c732c08fdb4c00f4e462b05e02251048fc6e81883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Feng, Zheng</creatorcontrib><creatorcontrib>Pignon, Jean-Christophe</creatorcontrib><creatorcontrib>Sharaf, Radwa</creatorcontrib><creatorcontrib>Romanov, Natalie</creatorcontrib><creatorcontrib>Doudement, Julien</creatorcontrib><creatorcontrib>Albacker, Lee A.</creatorcontrib><creatorcontrib>Kurata, Noriaki</creatorcontrib><creatorcontrib>Smith, Neil R.</creatorcontrib><creatorcontrib>Matsushita, Nobutoshi</creatorcontrib><creatorcontrib>Scheuenpflug, Juergen</creatorcontrib><collection>CrossRef</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Feng, Zheng</au><au>Pignon, Jean-Christophe</au><au>Sharaf, Radwa</au><au>Romanov, Natalie</au><au>Doudement, Julien</au><au>Albacker, Lee A.</au><au>Kurata, Noriaki</au><au>Smith, Neil R.</au><au>Matsushita, Nobutoshi</au><au>Scheuenpflug, Juergen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 5737: Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2022-06-15</date><risdate>2022</risdate><volume>82</volume><issue>12_Supplement</issue><spage>5737</spage><epage>5737</epage><pages>5737-5737</pages><issn>1538-7445</issn><eissn>1538-7445</eissn><abstract>Background: Following MET inhibitor and checkpoint inhibitor approvals, it is essential to identify cancer indications that harbor molecular alterations of interest and a thorough real-world molecular genomics based characterization of those tumors would allow to expand cancer specific indications that might benefit from MET and checkpoint inhibitors and shed light on exploring clinically efficacious combo strategies. Importantly, such an approach provides the end-to-end solutions that shall significantly contribute to clinical translation and/or back translation strategies for innovative cancer therapies. Methods: We systemically interrogated FoundationInsights®, a dataset of real-world molecular genomic tumor profiling from North American patients, and investigated the prevalence of MET amplifications, METex14 skipping and MET fusions prevalence in 62110 unique patient samples across five indications (lung adenocarcinoma [LUAD], esophageal/gastroesophageal-junction/stomach adenocarcinoma [Eso/GEJ/Sto], papillary renal cell carcinoma, hepatocellular carcinoma [HCC] and glioblastoma). MET alteration prevalence was further categorized based on tumor cell PD-L1 IHC status (22C3 pharmDx) and TMB status. Additionally, comprehensive text mining from clinicaltrials.gov and landscape overview were conducted. Results: MET amplification was the most frequent MET alteration examined with a prevalence ranging from 1.4% in HCC to 4.8% in Eso/GEJ/Sto. In HCC and LUAD, MET amplification prevalence was higher in tumors with high TMB (≥10 mutations/megabase, P&lt;0.05). In Eso/GEJ/Sto and LUAD, MET amplification occurrence was higher in PD-L1-high tumor vs. PD-L1-low or PD-L1-neg tumors (P&lt;0.05). METex14 skipping mutations were observed in LUAD (2.3%), rarely in the other five tumor types analyzed (≤0.1%). Lastly in LUAD, METex14 skipping mutations were more frequent in PD-L1 high tumors but not those with high TMB (P&lt;0.05). Text mining results indicate that- while most trials use MET amplification for patient stratification- there is a distinct tendency for MET inhibitor trials to increasingly include METex14 skipping as a major selection criterion as well. Conclusions: Real world genomics corroborated MET amplification as a predominant MET alteration across various indication. The potential clinical benefit to combine MET inhibitors with PD-1/PD-L1 blockades in specific indications and specific subsets of patients is further recognized. Collectively, the comprehensive molecular profiling &amp; text mining approaches will continue to guide application of precision medicine in clinical trial design based on appropriate biomarker selection. Citation Format: Zheng Feng, Jean-Christophe Pignon, Radwa Sharaf, Natalie Romanov, Julien Doudement, Lee A. Albacker, Noriaki Kurata, Neil R. Smith, Nobutoshi Matsushita, Juergen Scheuenpflug. Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5737.</abstract><doi>10.1158/1538-7445.AM2022-5737</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1538-7445
ispartof Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5737-5737
issn 1538-7445
1538-7445
language eng
recordid cdi_crossref_primary_10_1158_1538_7445_AM2022_5737
source EZB Electronic Journals Library
title Abstract 5737: Precision oncology driven real world clinical genomics data mining of MET alterations, TMB, and PDL-1 to empower indication agnostic patient enrollment and combination strategies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A49%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%205737:%20Precision%20oncology%20driven%20real%20world%20clinical%20genomics%20data%20mining%20of%20MET%20alterations,%20TMB,%20and%20PDL-1%20to%20empower%20indication%20agnostic%20patient%20enrollment%20and%20combination%20strategies&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Feng,%20Zheng&rft.date=2022-06-15&rft.volume=82&rft.issue=12_Supplement&rft.spage=5737&rft.epage=5737&rft.pages=5737-5737&rft.issn=1538-7445&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2022-5737&rft_dat=%3Ccrossref%3E10_1158_1538_7445_AM2022_5737%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c987-1702dcc07cc441b655e53527c732c08fdb4c00f4e462b05e02251048fc6e81883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true